NCT03456726 - Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

December 17, 2021

Study Completion Date

December 17, 2021

Conditions

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG

Tazemetostat

Tazemetostat will be provided as a 200 mg oral tablet.

Trial Locations (28)

Unknown

1004 Eisai Trial Site, Nagoya

1029 Eisai Trial Site, Nagoya

1020 Eisai Trial Site, Ōta

1007 Eisai Trial Site, Sapporo

1019 Eisai Trial Site, Kobe

1005 Eisai Trial Site, Tsukuba

1002 Eisai Trial Site, Isehara

1028 Eisai Trial Site, Yokohama

1021 Eisai Trial Site, Sendai

1013 Eisai Trial Site, Sayama

1006 Eisai Trial Site, Suita

1027 Eisai Trial Site, Suntou-gun

1026 Eisai Trial Site, Bunkyo-ku

1001 Eisai Trial Site, Chuo-ku

1025 Eisai Trial Site, Koto-ku

1017 Eisai Trial Site, Minato-ku

1022 Eisai Trial Site, Aomori

1010 Eisai Trial Site, Chiba

1012 Eisai Trial Site, Fukuoka

1016 Eisai Trial Site, Fukuoka

1011 Eisai Trial Site, Hiroshima

1024 Eisai Trial Site, Kumamoto

1003 Eisai Trial Site, Kyoto

1008 Eisai Trial Site, Kyoto

1023 Eisai Trial Site, Nagasaki

1009 Eisai Trial Site, Okayama

1015 Eisai Trial Site, Osaka

1018 Eisai Trial Site, Yamagata

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY